Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Immunome Inc Is A Biotechnology Company Focused On Developing First-In-Class Targeted Oncology Therapies. The Company Specializes In The Discovery, Design, Development, Manufacturing, And Commercialization Of Antibody-Drug Conjugates And Other Oncology Therapeutics. Its Pipeline Includes Varegacestat, An Investigational Oral Gamma Secretase Inhibitor That Reported Positive Topline Results In The Phase 3 Ringside Trial For Progressing Desmoid Tumors; Im-1021, A Ror1 Antibody-Drug Conjugate Under Evaluation In A Phase 1 Trial; And Im-3050, A Fap-Targeted Radioligand Therapy With Ind Clearance And A Planned Phase 1 Trial. The Company Is Also Advancing Preclinical Solid Tumor Adcs, Including Im-1617, Im-1340, And Im-1335.